Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals